Ambu maintains investment level for R&D despite narrower focus

The Danish medtech company’s new CEO Britt Meelby Jensen wants to develop fewer but better products through a new strategy – even so, the R&D budget won’t be lowered.

Photo: Ambu/PR

Ambu will continue to spend as much money as it does now on researching and developing new products – despite having just announced a new strategy, dubbed Zoom In, meaning the company will develop fewer endoscopy products in coming years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs